Protein-misfolding diseases and chaperone-based therapeutic approaches
- PMID: 16689923
- DOI: 10.1111/j.1742-4658.2006.05181.x
Protein-misfolding diseases and chaperone-based therapeutic approaches
Abstract
A large number of neurodegenerative diseases in humans result from protein misfolding and aggregation. Protein misfolding is believed to be the primary cause of Alzheimer's disease, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, Gaucher's disease and many other degenerative and neurodegenerative disorders. Cellular molecular chaperones, which are ubiquitous, stress-induced proteins, and newly found chemical and pharmacological chaperones have been found to be effective in preventing misfolding of different disease-causing proteins, essentially reducing the severity of several neurodegenerative disorders and many other protein-misfolding diseases. In this review, we discuss the probable mechanisms of several protein-misfolding diseases in humans, as well as therapeutic approaches for countering them. The role of molecular, chemical and pharmacological chaperones in suppressing the effect of protein misfolding-induced consequences in humans is explained in detail. Functional aspects of the different types of chaperones suggest their uses as potential therapeutic agents against different types of degenerative diseases, including neurodegenerative disorders.
Similar articles
-
Protein misfolding in neurodegenerative diseases.Neuropathol Appl Neurobiol. 2004 Jun;30(3):215-24. doi: 10.1111/j.1365-2990.2004.00558.x. Neuropathol Appl Neurobiol. 2004. PMID: 15175075 Review.
-
Modulation of neurodegeneration by molecular chaperones.Nat Rev Neurosci. 2005 Jan;6(1):11-22. doi: 10.1038/nrn1587. Nat Rev Neurosci. 2005. PMID: 15611723 Review.
-
Unraveling the mysteries of protein folding and misfolding.IUBMB Life. 2008 Dec;60(12):769-74. doi: 10.1002/iub.117. IUBMB Life. 2008. PMID: 18767168 Review.
-
How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.Pathobiology. 2007;74(3):145-58. doi: 10.1159/000103374. Pathobiology. 2007. PMID: 17643060 Review.
-
Mechanisms of disease II: cellular protein quality control.Semin Pediatr Neurol. 2007 Mar;14(1):15-25. doi: 10.1016/j.spen.2006.11.005. Semin Pediatr Neurol. 2007. PMID: 17331880 Review.
Cited by
-
Molecular dynamics simulations reveal structural instability of human trypsin inhibitor upon D50E and Y54H mutations.J Mol Model. 2013 Feb;19(2):521-8. doi: 10.1007/s00894-012-1565-2. Epub 2012 Sep 7. J Mol Model. 2013. PMID: 22955423
-
POLG2 disease variants: analyses reveal a dominant negative heterodimer, altered mitochondrial localization and impaired respiratory capacity.Hum Mol Genet. 2015 Sep 15;24(18):5184-97. doi: 10.1093/hmg/ddv240. Epub 2015 Jun 29. Hum Mol Genet. 2015. PMID: 26123486 Free PMC article.
-
Pathophysiology and treatment of cystinuria.Nat Rev Nephrol. 2010 Jul;6(7):424-34. doi: 10.1038/nrneph.2010.69. Epub 2010 Jun 1. Nat Rev Nephrol. 2010. PMID: 20517292 Review.
-
Disorders of FZ-CRD; insights towards FZ-CRD folding and therapeutic landscape.Mol Med. 2019 Dec 31;26(1):4. doi: 10.1186/s10020-019-0129-7. Mol Med. 2019. PMID: 31892318 Free PMC article. Review.
-
Protein Mutations and Stability, a Link with Disease: The Case Study of Frataxin.Biomedicines. 2022 Feb 11;10(2):425. doi: 10.3390/biomedicines10020425. Biomedicines. 2022. PMID: 35203634 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical